This report is no longer available. Click here to view our current reports or contact us to discuss a custom report.

If you have previously purchased this report then please use the download links on the right to download the files.

Ingeniería de tejidos 2018-2028: tecnologías, mercados, pronósticos

Oportunidades de equivalencia de tejidos vivos y tecnologías para su fabricación

Show All Description Contents, Table & Figures List FAQs Pricing Related Content
Tissue engineering, referring to the technologies that use physical, chemical, biological and engineering processes to control and direct the aggregate behaviour of cells, has become a field of increasing commercial interest. Though tissue engineering as a field has been around since the late 1970s, there have been few commercial successes. However, human understanding of biology, and our ability to manipulate it, has finally reached a point where complex living tissue equivalents are being developed. This report investigates this next generation of tissue engineering products and their potential in the next 10 years.
 
This report covers living tissue equivalents which contain both living cells and a 3D structure.
 
Applications
The biggest applications for engineered tissues are in research and development, and in medicine. This report discusses the following key applications of tissue engineering:
 
  • Testing of cosmetics and other consumer goods
  • Drug screening
  • Personalized medicine
  • Regenerative medicine
  • Cell-based biosensors
  • Food and other animal products
  • Aesthetics
 
Clinical Landscape
A chapter of this report is dedicated to the use of tissue engineering products in medicine. The following classes of tissue engineered therapies are highlighted:
 
  • Tissue engineered therapies with FDA marketing approval
  • Tissue engineered therapies close to IND submission
  • Competitive landscape of tissue engineered skin
  • Competitive landscape of tissue engineered cartilage
 
Additionally, a summary of ongoing clinical trials of tissue engineered products is provided, organized by trial phase, tissue type, and sponsor.
 
The rest of this chapter describes and discusses the dynamics of US and EU markets, with a look at relevant regulatory pathways, exemptions, and loopholes for tissue engineered products, as well as speculations on the future of regulating this novel class of therapy.
 
Market Forecasts
A market forecast for tissue engineered products is provided for the years 2018 - 2028, where the total value for tissue engineered products is predicted to surpass $4.8 billion. This market is broken down into key applications of therapies (clinical use) and tissue models (research use). Key players in both applications are presented, and the value chain and relevant business models are discussed.
 
Separately, a forecast for 3D bioprinters, an up-and-coming technology for tissue engineering, is also provided for the years 2018 - 2028.
 
Technology
A wide range of approaches are still being explored in tissue engineering, and this report covers both the most innovative and cutting-edge techniques as well as more established technologies. Technologies presented in this report are:
 
  • Semi-permeable membranes
  • Cell-laden hydrogels
  • 3D bioprinting
  • 3D printing (including thermoplastic extrusion, material jetting, stereolithography, selective laser sintering)
  • Decelluarization and recellularization of organs
  • Phase separation, freeze-drying, solvent casting and particle leaching, gas foaming
  • Electrospinning and melt electrospinning
  • Self-assembly and self-organization
Analyst access from IDTechEx
All report purchases include up to 30 minutes telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.
Further information
If you have any questions about this report, please do not hesitate to contact our report team at research@IDTechEx.com or call one of our sales managers:

AMERICAS (USA): +1 617 577 7890
ASIA (Japan and Korea): +81 3 3216 7209
EUROPE (UK) +44 1223 812300
1.EXECUTIVE SUMMARY
1.1.Overview
1.2.What is Tissue Engineering?
1.3.How are Tissues Engineered?
1.4.Key Players
1.5.Key Drivers
1.6.Key Opportunities
1.7.Tissue Engineered Products Market Forecast 2018 - 2028
1.8.Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028
1.9.Tissue Engineered Products for Research Use Market Forecast 2018 - 2028
1.10.Key Technologies
1.11.Key Challenges
2.INTRODUCTION
2.1.Report Scope
2.2.Advantages of 3D Cell Culture
2.3.Key Driver: Regenerative Medicine
2.4.Key Driver: Unmet Need in Organs for Transplant
2.5.Key Driver: Product Testing in Medicine
2.6.Key Driver: Avoiding Costly Drug Trial Failures
2.7.Key Driver: Product Testing in Consumer Products
2.8.Current Challenges: Biological
2.9.Current Challenges: Commercialization
2.10.Tissue Engineering in 2017
3.KEY OPPORTUNITIES
3.1.Overview
3.2.Testing of Cosmetics and Other Consumer Goods
3.3.Product Testing: Companies
3.4.Product Testing:
3.5.Drug Screening: Dermagenist
3.6.Drug Screening: Drug Development Process
3.7.Drug Screening: Benefits of Tissue Engineering
3.8.Drug Screening: Cancer
3.9.Drug Screening: Organ-on-a-chip
3.10.Drug Screening: Companies
3.11.Personalised Medicine
3.12.Cell-Based Biosensors
3.13.Food and Other Animal Products
3.14.Esthetics
4.TISSUE ENGINEERING CLINICAL LANDSCAPE
4.1.Overview
4.2.Regenerative Medicine
4.3.Competing Products
4.4.Competing Products: Advantages and Disadvantages
4.5.Commercial Activity
4.6.The US Market
4.7.Products with FDA Marketing Approval
4.8.The European Market
4.9.Clinical Trials
4.10.Clinical Trials: By Indication and Phase
4.11.Skin: Clinical Products
4.12.Cartilage: Clinical Products
4.13.Cartilage: NeoCart
4.14.Pre-Clinical Products
4.15.Regulatory Exemptions
4.16.Hospital Exemption Scheme
4.17.Hospital Exemption Scheme: Problems
4.18.21st Century Cures Act and the Regenerative Medicine Advanced Therapy Designation
4.19.Orphan Drug Designation
4.20.Scams and Unauthorized Treatments
4.21.Moving to Conditional Approval
4.22.Moving to Conditional Approval: Case Study
4.23.Learning from Medical Innovations
4.24.Future
5.MARKETS AND FORECASTS
5.1.Overview
5.2.Market Barriers
5.3.Tissue Engineering Value Chain
5.4.Tissue Engineering Value Chain: Discussion
5.5.Forecasts
5.6.Tissue Engineered Products Market Forecast 2018 - 2028
5.7.Companies with Marketed Clinical Products
5.8.Companies Developing Engineered Tissues for Clinical Use
5.9.Business Models: Engineered Autologous Tissues
5.10.Business Models: Cryopreserved Allogeneic Tissues
5.11.Tissue Engineered Products for Clinical Use Market Forecast 2018 - 2028
5.12.Companies Engineering Tissues for Research Use
5.13.Business Models: Tissues for Research Use
5.14.Tissue Engineered Products for Research Use Market Forecast 2018 - 2028
5.15.Companies Producing Organ-On-A-Chips
5.16.Companies Producing Lab-Grown Meat
5.17.Scaffold Manufacturers
5.18.3D Bioprinter Market and Forecasts
5.19.Growing 3D Bioprinting Market
5.20.3D Bioprinting Value Chain
5.21.3D Bioprinting Value Chain: Discussion
5.22.3D Bioprinters by Cost and Technology
5.23.3D Bioprinter Market Forecast 2018 - 2028
5.24.Caveats
6.TISSUE ENGINEERING TECHNOLOGIES
6.1.Overview
7.ESTABLISHED TECHNOLOGIES
7.1.Introduction
7.2.Semi-Permeable Membranes
7.3.Key Semi-Permeable Membrane Manufacturers
7.4.Hydrogels
7.5.Cell-Laden Hydrogels
7.6.Cell-Laden Hydrogels: Companies
7.7.Cell-Laden Hydrogels: SWOT Analysis
8.3D BIOPRINTING
8.1.Introduction
8.2.3D Bioprinting Process
8.3.Comparison of Key Specifications
8.4.3D Bioprinting Technology Comparison
8.5.Inkjet: Thermal
8.6.Inkjet: Piezoelectric
8.7.Inkjet: Companies
8.8.Inkjet: SWOT Analysis
8.9.Extrusion: Pneumatic
8.10.Extrusion: Mechanical
8.11.Extrusion: Companies
8.12.Extrusion: Example
8.13.Extrusion: SWOT Analysis
8.14.LIFT: Laser-Induced Forward Transfer
8.15.LIFT: Companies
8.16.LIFT: SWOT Analysis
8.17.Microvalve: Solenoid
8.18.Microvalve: Companies
8.19.Microvalve: SWOT Analysis
8.20.Industry-wide Technical Challenges
8.21.The Ideal 3D Bioprinter
8.22.Animal Studies
8.23.Future Technological Directions
9.SCAFFOLD TECHNOLOGIES
9.1.Tissue Engineering Scaffolds
9.2.Ideal Scaffold
10.3D PRINTING
10.1.Introduction
10.2.Examples of 3D Printed Medical Products
10.3.Thermoplastic Extrusion
10.4.Thermoplastic Extrusion: Example
10.5.Thermoplastic Extrusion: Key Manufacturers
10.6.Thermoplastic Extrusion: SWOT Analysis
10.7.Material Jetting
10.8.Material Jetting: Key Players
10.9.Material Jetting: SWOT Analysis
10.10.Stereolithography
10.11.Stereolithography: Key Players
10.12.Stereolithography: SWOT Analysis
10.13.Stereolithography: Microstereolithography
10.14.Stereolithography: Projection
10.15.Stereolithography: Multiphoton Lithography
10.16.Stereolithography: Multiphoton Lithography: Example
10.17.Selective Laser Sintering
10.18.Selective Laser Sintering: Key Players
10.19.Selective Laser Sintering: SWOT Analysis
11.DECELLULARIZED ORGANS
11.1.Introduction
11.2.History
11.3.Decellularization
11.4.Recellularization
11.5.Companies
11.6.Future Technological Directions
11.7.Bioreactors
12.OTHER SCAFFOLD TECHNOLOGIES
12.1.Introduction
12.2.Phase Separation
12.3.Freeze-Drying
12.4.Freeze-Drying: Companies
12.5.Solvent Casting and Particle Leaching
12.6.Gas Foaming
12.7.Chemical Processes: Strengths and Weaknesses
12.8.Textile Technologies
12.9.Electrospinning
12.10.Cell Electrospinning
12.11.Electrospinning: Examples
12.12.Electrospinning: SWOT Analysis
12.13.Melt Electrospinning
12.14.Melt Electrospinning: SWOT Analysis
12.15.Electrospinning: Companies
13.SCAFFOLDLESS TECHNOLOGIES
13.1.Introduction
13.2.Cell Spheroids
13.3.Cell Spheroids: Self-Assembly
13.4.Cell Spheroids: Self-Organization
13.5.Cell Spheroids: Rotational Culture Equipment
13.6.Cell Spheroids: Key Companies
13.7.Cell Sheets
13.8.Cell Therapy Devices
13.9.Cell Therapy Devices: Companies
14.TISSUE ENGINEERING CHALLENGES
14.1.Industry-Wide Technical Challenges
14.2.Biopreservation
14.3.Vascularization
15.COMPANY PROFILES
15.1.3D Bioprinting Solutions/ Vivax Bio
15.2.3D Biotek
15.3.3Dynamic Systems Ltd
15.4.Aether Inc.
15.5.Aspect Biosystems
15.6.ATERA
15.7.Avery Therapeutics
15.8.AxoSim
15.9.BioBots
15.10.BioDan Group
15.11.BIOLIFE4D
15.12.Cellenion SASU
15.13.Cellf BIO
15.14.Cellink
15.15.CUTISS
15.16.Digilab Inc.
15.17.GeSiM
15.18.Hesperos
15.19.Histogenics
15.20.Lena Biosciences
15.21.Microdrop Technologies GmbH
15.22.MicroFab Technologies
15.23.Mimetas
15.24.PeptiGel Design Ltd
15.25.Poietis
15.26.Prellis Biologics
15.27.Regemat 3D
15.28.RegenHU
15.29.SE3D
15.30.Sichuan Revotek Co. Ltd.
15.31.Synthecon
15.32.Tara Biosystems
15.33.TissUse
15.34.Upside Biotechnologies
 

About IDTechEx reports

What are the qualifications of the people conducting IDTechEx research?

Content produced by IDTechEx is researched and written by our technical analysts, each with a PhD or master's degree in their specialist field, and all of whom are employees. All our analysts are well-connected in their fields, intensively covering their sectors, revealing hard-to-find information you can trust.

How does IDTechEx gather data for its reports?

By directly interviewing and profiling companies across the supply chain. IDTechEx analysts interview companies by engaging directly with senior management and technology development executives across the supply chain, leading to revealing insights that may otherwise be inaccessible.
 
Further, as a global team, we travel extensively to industry events and companies to conduct in-depth, face-to-face interviews. We also engage with industry associations and follow public company filings as secondary sources. We conduct patent analysis and track regulatory changes and incentives. We consistently build on our decades-long research of emerging technologies.
 
We assess emerging technologies against existing solutions, evaluate market demand and provide data-driven forecasts based on our models. This provides a clear, unbiased outlook on the future of each technology or industry that we cover.

What is your forecast methodology?

We take into account the following information and data points where relevant to create our forecasts:
  • Historic data, based on our own databases of products, companies' sales data, information from associations, company reports and validation of our prior market figures with companies in the industry.
  • Current and announced manufacturing capacities
  • Company production targets
  • Direct input from companies as we interview them as to their growth expectations, moderated by our analysts
  • Planned or active government incentives and regulations
  • Assessment of the capabilities and price of the technology based on our benchmarking over the forecast period, versus that of competitive solutions
  • Teardown data (e.g. to assess volume of materials used)
  • From a top-down view: the total addressable market
  • Forecasts can be based on an s-curve methodology where appropriate, taking into account the above factors
  • Key assumptions and discussion of what can impact the forecast are covered in the report.

How can I be confident about the quality of work in IDTechEx reports?

Based on our technical analysts and their research methodology, for over 25 years our work has regularly received superb feedback from our global clients. Our research business has grown year-on-year.
 
Recent customer feedback includes:
"It's my first go-to platform"
- Dr. Didi Xu, Head of Foresight - Future Technologies, Freudenberg Technology Innovation
 
"Their expertise allows us to make data-driven, strategic decisions and ensures we remain aligned with the latest trends and opportunities in the market."
- Ralf Hug, Global Head of Product Management & Marketing, Marquardt

What differentiates IDTechEx reports?

Our team of in-house technical analysts immerse themselves in industries over many years, building deep expertise and engaging directly with key industry players to uncover hard-to-find insights. We appraise technologies in the landscape of competitive solutions and then assess their market demand based on voice-of-the-customer feedback, all from an impartial point of view. This approach delivers exceptional value to our customers—providing high-quality independent content while saving customers time, resources, and money.

Why should we pick IDTechEx research over AI research?

A crucial value of IDTechEx research is that it provides information, assessments and forecasts based on interviews with key people in the industry, assessed by technical experts. AI is trained only on content publicly available on the web, which may not be reliable, in depth, nor contain the latest insights based on the experience of those actively involved in a technology or industry, despite the confident prose.

How can I justify the ROI of this report?

Consider the cost of the IDTechEx report versus the time and resources required to gather the same quality of insights yourself. IDTechEx analysts have built up an extensive contact network over many years; we invest in attending key events and interviewing companies around the world; and our analysts are trained in appraising technologies and markets.
 
Each report provides an independent, expert-led technical and market appraisal, giving you access to actionable information immediately, rather than you having to spend months or years on your own market research.

Can I speak to analysts about the report content?

All report purchases include up to 30 minutes of telephone time with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This needs to be used within three months of purchasing the report.

What is the difference between a report and subscription?

A subscription from IDTechEx can include more reports, access to an online information platform with continuously updated information from our analysts, and access to analysts directly.

Before purchasing, I have some questions about the report, can I speak to someone?

Please email research@idtechex.com stating your location and we will quickly respond.

About IDTechEx

Who are IDTechEx's customers?

IDTechEx has served over 35,000 customers globally. These range from large corporations to ambitious start-ups, and from Governments to research centers. Our customers use our work to make informed decisions and save time and resources.

Where is IDTechEx established?

IDTechEx was established in 1999, and is headquartered in Cambridge, UK. Since then, the company has significantly expanded and operates globally, having served customers in over 80 countries. Subsidiary companies are based in the USA, Germany and Japan.

Questions about purchasing a report

How do I pay?

In most locations reports can be purchased by credit card, or else by direct bank payment.

How and when do I receive access to IDTechEx reports?

When paying successfully by credit card, reports can be accessed immediately. For new customers, when paying by bank transfer, reports will usually be released when the payment is received. Report access will be notified by email.

How do I assign additional users to the report?

Users can be assigned in the report ordering process, or at a later time by email.

Can I speak to someone about purchasing a report?

Please email research@idtechex.com stating your location and we will quickly respond.
 
The market for tissue engineered products to exceed $4.8 billion by the year 2028

Report Statistics

Slides 279
Companies 34
Forecasts to 2028
 

Customer Testimonial

quote graphic
"The resources provided by IDTechEx, such as their insightful reports and analysis, engaging webinars, and knowledgeable analysts, serve as valuable tools and information sources... Their expertise allows us to make data-driven, strategic decisions and ensures we remain aligned with the latest trends and opportunities in the market."
Global Head of Product Management and Marketing
Marquardt GmbH
 
 
 

Subscription Enquiry